Literature DB >> 19649707

Genome-wide microarray analysis of the differential neuroprotective effects of antioxidants in neuroblastoma cells overexpressing the familial Parkinson's disease alpha-synuclein A53T mutation.

Lei Ma1, Tracy T Cao, Geeta Kandpal, Lee Warren, J Fred Hess, Guy R Seabrook, William J Ray.   

Abstract

In Parkinson's disease substantia nigra neurons degenerate likely due to oxidative damage interacting with genetic risk factors. Here, SH-SY5Y cells expressing wild-type or A53T alpha-synuclein had increased sensitivity to methyl-4-phenylpyridinium iodide (MPP(+)), which induces mitochondrial dysfunction, and 6-hydroxydopamine (6-OHDA), which causes oxidative stress. Edaravone protected only against MPP(+), and EGCG ((-)-epigallocatechin-3-O-gallate) protected only against 6-OHDA. Thus genomic responses to MPP(+) and 6-OHDA in the presence of these antioxidants were analyzed using microarrays. Pathway analysis indicated that MPP(+) activated p53 (P < 0.001) while 6-OHDA induced the Nrf2 antioxidative stress response (P < 0.0001). EGCG was more effective at blocking 6-OHDA-mediated genomic responses, while edaravone was more effective against MPP(+). We identified 32 genes that responded to both toxins except in the presence of an effective anti-oxidant; eight are transcription factors and potentially constitute a stress-response transcriptional network. These data provide insights into the mechanisms of neurotoxicity and identifies genes that might mediate antioxidant efficacy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19649707     DOI: 10.1007/s11064-009-0038-1

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  61 in total

1.  Activation of the unfolded protein response in Parkinson's disease.

Authors:  J J M Hoozemans; E S van Haastert; P Eikelenboom; R A I de Vos; J M Rozemuller; W Scheper
Journal:  Biochem Biophys Res Commun       Date:  2007-01-17       Impact factor: 3.575

2.  Rosetta error model for gene expression analysis.

Authors:  Lee Weng; Hongyue Dai; Yihui Zhan; Yudong He; Sergey B Stepaniants; Douglas E Bassett
Journal:  Bioinformatics       Date:  2006-03-07       Impact factor: 6.937

3.  Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes.

Authors:  R Venugopal; A K Jaiswal
Journal:  Oncogene       Date:  1998-12-17       Impact factor: 9.867

4.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.

Authors:  R Krüger; W Kuhn; T Müller; D Woitalla; M Graeber; S Kösel; H Przuntek; J T Epplen; L Schöls; O Riess
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

5.  Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene.

Authors:  R Venugopal; A K Jaiswal
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

6.  Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation.

Authors:  S Kanda; J F Bishop; M A Eglitis; Y Yang; M M Mouradian
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

7.  Initiation and synergistic fibrillization of tau and alpha-synuclein.

Authors:  Benoit I Giasson; Mark S Forman; Makoto Higuchi; Lawrence I Golbe; Charles L Graves; Paul T Kotzbauer; John Q Trojanowski; Virginia M-Y Lee
Journal:  Science       Date:  2003-04-25       Impact factor: 47.728

8.  Edaravone protects against MPP+ -induced cytotoxicity in rat primary cultured astrocytes via inhibition of mitochondrial apoptotic pathway.

Authors:  Hui Chen; Sen Wang; Jian-Hua Ding; Gang Hu
Journal:  J Neurochem       Date:  2008-07-15       Impact factor: 5.372

9.  Development of the mesencephalic dopaminergic neuron system is compromised in the absence of neurogenin 2.

Authors:  E Andersson; J B Jensen; M Parmar; F Guillemot; A Björklund
Journal:  Development       Date:  2006-01-05       Impact factor: 6.868

Review 10.  Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?

Authors:  V Bogaerts; J Theuns; C van Broeckhoven
Journal:  Genes Brain Behav       Date:  2007-08-03       Impact factor: 3.449

View more
  10 in total

1.  TMEM175 deficiency impairs lysosomal and mitochondrial function and increases α-synuclein aggregation.

Authors:  Sarah Jinn; Robert E Drolet; Paige E Cramer; Andus Hon-Kit Wong; Dawn M Toolan; Cheryl A Gretzula; Bhavya Voleti; Galya Vassileva; Jyoti Disa; Marija Tadin-Strapps; David J Stone
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-13       Impact factor: 11.205

Review 2.  Thiol-redox signaling, dopaminergic cell death, and Parkinson's disease.

Authors:  Aracely Garcia-Garcia; Laura Zavala-Flores; Humberto Rodriguez-Rocha; Rodrigo Franco
Journal:  Antioxid Redox Signal       Date:  2012-05-03       Impact factor: 8.401

3.  Fbxl18 targets LRRK2 for proteasomal degradation and attenuates cell toxicity.

Authors:  Xiaodong Ding; Sandeep K Barodia; Lisha Ma; Matthew S Goldberg
Journal:  Neurobiol Dis       Date:  2016-11-24       Impact factor: 5.996

4.  Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction.

Authors:  Kiyoshi Kikuchi; Ko-Ichi Kawahara; Hisaaki Uchikado; Naohisa Miyagi; Terukazu Kuramoto; Tomoya Miyagi; Yoko Morimoto; Takashi Ito; Salunya Tancharoen; Naoki Miura; Kazunori Takenouchi; Yoko Oyama; Binita Shrestha; Fumiyo Matsuda; Yoshihiro Yoshida; Shinihiro Arimura; Kentaro Mera; Ko-Ichi Tada; Narimasa Yoshinaga; Ryuichi Maenosono; Yoshiko Ohno; Teruto Hashiguchi; Ikuro Maruyama; Minoru Shigemori
Journal:  Exp Ther Med       Date:  2011-06-07       Impact factor: 2.447

Review 5.  Mitochondrial dysfunction and oxidative stress in Parkinson's disease.

Authors:  Sudhakar Raja Subramaniam; Marie-Francoise Chesselet
Journal:  Prog Neurobiol       Date:  2013-04-30       Impact factor: 11.685

6.  Functionalization of the TMEM175 p.M393T variant as a risk factor for Parkinson disease.

Authors:  Sarah Jinn; Cornelis Blauwendraat; Dawn Toolan; Cheryl A Gretzula; Robert E Drolet; Sean Smith; Mike A Nalls; Jacob Marcus; Andrew B Singleton; David J Stone
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

Review 7.  Epigallocatechin-3-gallate: A phytochemical as a promising drug candidate for the treatment of Parkinson's disease.

Authors:  Yumin Wang; Shuang Wu; Qiang Li; Weihong Lang; Wenjing Li; Xiaodong Jiang; Zhirong Wan; Jichao Chen; Hongquan Wang
Journal:  Front Pharmacol       Date:  2022-09-12       Impact factor: 5.988

8.  Neuroprotective and anti-inflammatory effects of the flavonoid-enriched fraction AF4 in a mouse model of hypoxic-ischemic brain injury.

Authors:  Paul G W Keddy; Kate Dunlop; Jordan Warford; Michel L Samson; Quinton R D Jones; H P Vasantha Rupasinghe; George S Robertson
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

Review 9.  NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases.

Authors:  Ángel Cores; Marta Piquero; Mercedes Villacampa; Rafael León; J Carlos Menéndez
Journal:  Biomolecules       Date:  2020-06-14

10.  NRF2 as a Therapeutic Target in Neurodegenerative Diseases.

Authors:  Mikah S Brandes; Nora E Gray
Journal:  ASN Neuro       Date:  2020 Jan-Dec       Impact factor: 4.146

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.